Live Breaking News & Updates on Relay Therapeutics
Stay updated with breaking news from Relay therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Zenocutuzumab elicited clinical activity with a tolerable safety profile in patients with advanced non–small cell lung cancer harboring NRG1 fusions, including those with prior afatinib exposure, according to findings from the ongoing, phase 1/2 eNRGy trial. ....
Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Free Report) was the recipient of a significant decrease in short interest in the month of October. As of October 15th, there was short interest totalling 13,770,000 shares, a decrease of 29.0% from the September 30th total of 19,400,000 shares. Currently, 16.3% of the company’s shares are short sold. […] ....
Relay Therapeutics to Announce Third Quarter 2023 Financial Results and Corporate Highlights on November 2, 2023 tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Free Report)’s stock price reached a new 52-week low during trading on Thursday . The company traded as low as $6.80 and last traded at $6.88, with a volume of 76201 shares trading hands. The stock had previously closed at $7.08. Wall Street Analysts Forecast Growth RLAY has been […] ....